Vespina Lifesciences Inc. plans to develop to proof-of-concept a potential best-in-class compound with the potential to treat certain types of inflammatory diseases including pulmonary indications with poor therapeutic options as well as non-pulmonary inflammatory diseases. The compound was originally discovered and characterized at Denmark-based Neuprozyme Therapeutics ApS. There are upwards of 70,000 patients newly diagnosed with bronchiectasis in the US every year as more than half of the 16+ million patients diagnosed with COPD in the US likely also have concurrent bronchiectasis. There are no approved treatments that specifically address the underlying mechanism of disease.
